Přejít k obsahu
Merck
Všechny fotografie(1)

Hlavní dokumenty

420119

Sigma-Aldrich

SP600125

≥98% (HPLC), solid, JNK inhibitor, Calbiochem®

Synonyma:

JNK Inhibitor II, SAPK Inhibitor II, Anthra[1,9- cd]pyrazol-6(2 H)-one, 1,9-pyrazoloanthrone, SP600125

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen

Vybrat velikost

5 MG
2 360,00 Kč
25 MG
7 180,00 Kč
50 MG
11 300,00 Kč
1 G
61 300,00 Kč

2 360,00 Kč


Na skladěpodrobné informace



Vybrat velikost

Změnit zobrazení
5 MG
2 360,00 Kč
25 MG
7 180,00 Kč
50 MG
11 300,00 Kč
1 G
61 300,00 Kč

About This Item

Empirický vzorec (Hillův zápis):
C14H8N2O
Číslo CAS:
Molekulová hmotnost:
220.23
UNSPSC Code:
12352200
NACRES:
NA.77

2 360,00 Kč


Na skladěpodrobné informace


Název produktu

JNK Inhibitor II, JNK Inhibitor II. SP600125, CAS 129-56-6, is a potent, cell-permeable, selective, and ATP competitive inhibitor of c-Jun N-terminal kinase (JNK; IC₅₀ = 40 nM for JNK-1 & JNK-2 & 90 nM for JNK-3).

Quality Level

description

RTECS - CB4585000

assay

≥98% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

yellow-orange

solubility

DMSO: 15 mg/mL

shipped in

ambient

storage temp.

−20°C

SMILES string

[nH]1nc2c3c1[c]4[c]([c]([c]3=CC=C2)=O)=CC=CC=4

InChI

1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7H,(H,15,16)

InChI key

ACPOUJIDANTYHO-UHFFFAOYSA-N

General description

A potent, cell-permeable, selective, and reversible inhibitor of c-Jun N-terminal kinase (JNK) (IC50 = 40 nM for JNK-1 and JNK-2 and 90 nM for JNK-3). The inhibition is competitive with respect to ATP. Exhibits over 300-fold greater selectivity for JNK as compared to ERK1 and p38-2 MAP kinases. Inhibits the phosphorylation of c-Jun and blocks cellular expression of IL-2, IFN-γ, TNF-α, and COX-2. Blocks IL-1-induced accumulation of phospho-Jun and induction of c-Jun transcription. A 50 mM (5 mg/454 µl) solution of JNK Inhibitor II (Cat. No. 420128) in DMSO is also available.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
JNK 1, JNK 2, JNK 3
Product competes with ATP.
Reversible: yes
Target IC50: 40 nM for JNK-1 and JNK-2 and 90 nM for JNK-3

Packaging

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)

Preparation Note

For every 10 µM concentration of JNK Inhibitor II, include 0.1% DMSO in the culture medium. Pre-warming of culture medium and addition of BSA to the medium may enhance its solubility.

Reconstitution

Following reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 2 months at -20°C.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Hu Xu et al.
American journal of physiology. Heart and circulatory physiology, 300(3), H913-H921 (2010-12-28)
High-mobility group box 1 (HMGB1) is a nuclear protein that has been implicated in the myocardial inflammation and injury induced by ischemia-reperfusion (I/R). The purpose of the present study was to assess the role of HMGB1 in myocardial apoptosis induced
Wenjuan Sun et al.
Frontiers in pharmacology, 13, 807452-807452 (2022-05-03)
Inflammation and apoptosis are the major contributors to the mechanisms of acute kidney injury (AKI) due to renal ischemia-reperfusion injury (IRI). Maslinic acid (MA), a pentacyclic triterpene acid mostly found in dietary plants, the current study was to demonstrate the
Kaiyuan Wang et al.
The Journal of clinical investigation, 130(7), 3603-3620 (2020-06-03)
Emerging immune therapy, such as with the anti-programmed cell death-1 (anti-PD-1) monoclonal antibody nivolumab, has shown efficacy in tumor suppression. Patients with terminal cancer suffer from cancer pain as a result of bone metastasis and bone destruction, but how PD-1
Dai-Xu Li et al.
General physiology and biophysics, 39(6), 545-555 (2020-11-24)
Cardiovascular disease (CVD) states are associated with endothelial dysfunction (ED) and increased production of ROS in endothelial cells. The present study aimed to explore the protective effects of antioxidant protein peroxiredoxin 6 (PRDX6) on angiotensin II (AngII)‑induced human umbilical vein
Fiorella Carla Grandi et al.
Science advances, 6(11), eaay5352-eaay5352 (2020-03-24)
Aging or injury leads to degradation of the cartilage matrix and the development of osteoarthritis (OA). Because of a paucity of single-cell studies of OA cartilage, little is known about the interpatient variability in its cellular composition and, more importantly

Questions

Reviews

No rating value

Active Filters

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.